Abstract
Background: Epilepsy affects about 70 million people worldwide, nearly 90% of whom live in developing countries. Epilepsy is surrounded by myths and stigma in these countries. Discrimination and social stigmatization are difficult obstacles for patients to overcome. Knowledge, attitudes and practices towards epilepsy are often inadequate, even sometimes totally false and then dangerous.
Methods: The goal was to present the situation and analyse the determinants of using antiepileptic drugs in developing countries. Results: The treatment gap exceeds 75% in most low-income countries, and could be even higher in rural areas. Reasons for that are low accessibility, availability, and/or affordability, lack of trained medical personnel and the associated beliefs and stigma. The interactions between drugs or due to other factors, such as malnutrition, are frequent. A long-lasting treatment is not usual for populations in developing countries due to cultural beliefs. The traditional healers are the first ones consulted in such a context, then delaying the entry in the “modern” medical care system. Conclusion: Information and education campaigns are mandatory among the general population and among the medical and paramedical staff to make progress on the management of epilepsy in developing countries.Keywords: Epilepsy, developing countries, antiepileptics drugs, treatment gap, stigma, patients.
Current Pharmaceutical Design
Title:Antiepileptic Treatments in Developing Countries
Volume: 23 Issue: 37
Author(s): Jeremy Jost*, Athanase Millogo and Pierre-Marie Preux
Affiliation:
- INSERM, Univ. Limoges, CHU Limoges, UMR_S 1094, Tropical Neuroepidemiology, Institute of Neuroepidemiology and Tropical Neurology, CNRS FR 3503 GEIST, F-87000 Limoges,France
Keywords: Epilepsy, developing countries, antiepileptics drugs, treatment gap, stigma, patients.
Abstract: Background: Epilepsy affects about 70 million people worldwide, nearly 90% of whom live in developing countries. Epilepsy is surrounded by myths and stigma in these countries. Discrimination and social stigmatization are difficult obstacles for patients to overcome. Knowledge, attitudes and practices towards epilepsy are often inadequate, even sometimes totally false and then dangerous.
Methods: The goal was to present the situation and analyse the determinants of using antiepileptic drugs in developing countries. Results: The treatment gap exceeds 75% in most low-income countries, and could be even higher in rural areas. Reasons for that are low accessibility, availability, and/or affordability, lack of trained medical personnel and the associated beliefs and stigma. The interactions between drugs or due to other factors, such as malnutrition, are frequent. A long-lasting treatment is not usual for populations in developing countries due to cultural beliefs. The traditional healers are the first ones consulted in such a context, then delaying the entry in the “modern” medical care system. Conclusion: Information and education campaigns are mandatory among the general population and among the medical and paramedical staff to make progress on the management of epilepsy in developing countries.Export Options
About this article
Cite this article as:
Jost Jeremy *, Millogo Athanase and Preux Pierre-Marie, Antiepileptic Treatments in Developing Countries, Current Pharmaceutical Design 2017; 23(37) . https://dx.doi.org/10.2174/1381612823666170809103202
DOI https://dx.doi.org/10.2174/1381612823666170809103202 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Bipolar Spectrum Disorder: Origins and State of the Art
Current Psychiatry Reviews Single Channel EEG Signal for Automatic Detection of Absence Seizure Using Convolutional Neural Network
Recent Advances in Computer Science and Communications 2,3-Disubtituted Thiazolidin-4-ones: Novel Class of Anticonvulsant Agents
Letters in Drug Design & Discovery Supplements, Diets and Other Complementary and Alternative Interventions in Adolescent Mental Health
Adolescent Psychiatry Transcriptional Dys-regulation in Anxiety and Major Depression: 5-HT1A Gene Promoter Architecture as a Therapeutic Opportunity
Current Pharmaceutical Design Subject Index To Volume 6
Current Topics in Medicinal Chemistry Childhood Infectious Encephalitis: An Overview of Clinical Features, Investigations, Treatment, and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Synthesis and Antioxidant Activity of Indole Derivatives Containing 4-Substituted Piperazine Moieties
Letters in Drug Design & Discovery Current Applications of Artificial Neural Networks in Biochemistry with Emphasis on Cancer Research
Current Biochemical Engineering (Discontinued) Molecular Biomarkers for Amyotrophic Lateral Sclerosis
Current Bioinformatics Novel Therapeutic Effects of the Anti-Convulsant, Zonisamide, on Parkinsons Disease
Current Pharmaceutical Design Mining for Protein Kinase Substrates: Integration of Biochemistry, Genetics and Proteomics
Current Proteomics Warming Up to New Possibilities with the Capsaicin Receptor TRPV1: mTOR, AMPK, and Erythropoietin
Current Neurovascular Research β -Amyloid: A Disease Target or a Synaptic Regulator Affecting Age-Related Neurotransmitter Changes?
Current Pharmaceutical Design Recent Advancement in Computer-Aided Drug Design
Current Pharmaceutical Design Combined Virtual Screening Strategies
Current Computer-Aided Drug Design Current & Future Therapies of Erectile Dysfunction in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) PET Imaging in Clinical Drug Abuse Research
Current Pharmaceutical Design Routine Collection of Patient-Reported Outcomes in an HIV Clinic Setting:The First 100 Patients
Current HIV Research Environment, Physical Activity, and Neurogenesis: Implications for Prevention and Treatment of Alzhemiers Disease
Current Alzheimer Research